|Year : 2019 | Volume
| Issue : 2 | Page : 43-48
Hemodynamic responses of patients with stable coronary artery disease to a comedy film: study protocol for a randomized controlled trial
Rosane Maria Nery1, Raquel Petry Buhler1, Débora Santos Macedo2, Juliana Maia Delfino2, Filipe Ferrari2, Anderson Donelli Silveira3, Marco Aurélio Lumertz Saffi1, Ricardo Stein3
1 Exercise Cardiology Research Group (CardioEX), Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Rehabilitation Division; Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
2 Exercise Cardiology Research Group (CardioEX), Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Rehabilitation Division; Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
3 Exercise Cardiology Research Group (CardioEX), Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Rehabilitation Division; Hospital de Clínicas de Porto Alegre; Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
|Date of Submission||11-Feb-2019|
|Date of Acceptance||15-Mar-2019|
|Date of Web Publication||9-Jul-2019|
Exercise Cardiology Research Group (CardioEX), Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Rehabilitation Division; Hospital de Clínicas de Porto Alegre; Universidade Federal do Rio Grande do Sul, Porto Alegre
Source of Support: None, Conflict of Interest: None
Clinical trial registration NCT02824120
Background and objective: Alternative and complementary interventions have been developed in an attempt to improve treatment and increase the survival of patients with coronary artery disease (CAD); one such intervention is laughter therapy. However, there is very little information on the effect of this therapeutic modality in patients with CAD. The present randomized controlled trial will compare the effect of 24 sessions of a comedy film and neutral documentary in patients with CAD.
Subjects and methods: This is a randomized, parallel-design, examiner-blinded and controlled clinical trial. Patients with stable CAD of both sexes, aged ≥ 18 years, receiving regular follow-up at a public university hospital in Southern Brazil will be included in the trial. Subjects will be randomly allocated to an intervention group (will watch a 30-minute comedy film) or a control group (will watch a 30-minute neutral documentary). Patient recruitment will end in December 2019. Analysis of the primary outcome measure will be completed in December 2019. The current protocol version is 1.0. The study protocol was approved by the Institutional Review Board of Hospital de Clínicas de Porto Alegre (protocol No. 13-0124) on July 9, 2013.
Outcome measures: The primary outcomes are the difference from baseline to the 2-month time point (corresponding to 24 sessions) in endothelial function, as assessed by brachial artery flow-mediated dilation measurement and peak oxygen consumption (peak VO2) on cardiopulmonary exercise testing. Secondary outcome measures include concentrations of inflammatory markers in blood, biochemical parameters, and quality of life.
Discussion: This study will provide new evidence on the effect of an easy-to-use, inexpensive, readily deployable non pharmacological therapeutic intervention for patients with stable CAD.
Trial registration: ClinicalTrials.gov identifier: NCT02824120. Date of registration: July 6, 2016.
Keywords: laughter therapy; endothelium; flow-mediated dilation; functional capacity; blood biochemistry; quality of life
|How to cite this article:|
Nery RM, Buhler RP, Macedo DS, Delfino JM, Ferrari F, Silveira AD, Lumertz Saffi MA, Stein R. Hemodynamic responses of patients with stable coronary artery disease to a comedy film: study protocol for a randomized controlled trial. Clin Trials Degener Dis 2019;4:43-8
|How to cite this URL:|
Nery RM, Buhler RP, Macedo DS, Delfino JM, Ferrari F, Silveira AD, Lumertz Saffi MA, Stein R. Hemodynamic responses of patients with stable coronary artery disease to a comedy film: study protocol for a randomized controlled trial. Clin Trials Degener Dis [serial online] 2019 [cited 2022 Jun 27];4:43-8. Available from: https://www.clinicaltdd.com/text.asp?2019/4/2/43/260956
Funding: This study was supported by Funding for Research and Events from the Hospital de Clínicas de Porto Alegre (FIPE-HCPA).
| Introduction|| |
Cardiovascular diseases are the leading cause of death worldwide, and lifestyle changes are seen as key to improving this scenario. Cardiac rehabilitation is considered a class I intervention, which provides net benefit to overall health, and is strongly recommended by most guidelines. Despite this, less than 30% of patients who have experienced a cardiovascular event in the United States are engaged in a supervised cardiac rehabilitation program, even when they are eligible for such non pharmacological therapeutic strategies. Studies on this topic have been heterogeneous in terms of the type, duration, and intensity of physical training; in addition, they have not covered complementary modalities such as laughter therapy.,,,
The idea that laughter can produce positive health benefits has become increasingly popular both among health care providers and the general public. However, considering the multifaceted nature of the concepts of humor and “sense of humor,” their potential health benefits are difficult to characterize and measure. Researchers who have examined the humor-health dyad have conceptualized humor in different ways: as a personality trait, an emotional response, a mental process, or a therapeutic intervention. In this particular aspect, the concept of humor adopted also influences the design of research projects on the topic.
Laughter is more than a visual and vocal behavior. It always involves a series of physiological changes, including skeletal muscle contractions, increased heart rate (secondary to catecholamine release), and hyperventilation, which promotes increased maximal breathing and, consequently, an increase in oxyhemoglobin saturation. Studies have shown that laughter therapy can improve quality of life, psychological status, increase total lung capacity, and decrease pulmonary hyperinflation in patients with chronic obstructive pulmonary disease.,
Sugawara et al. evaluated endothelial function (measured by flow-mediated dilation, FMD) in healthy adults who watched a 30-minute documentary or a comedy film session, and observed better results after the latter. However, to the best of our knowledge, no randomized controlled trial has been conducted to investigate the impact of laughter therapy in patients with stable coronary artery disease (CAD).
Laughter therapy is an inexpensive non pharmacological intervention that requires very little investment in time or infrastructure. There are few contraindications, the risk of side effects is very low, and it can be readily prescribed by health practitioners. In healthy individuals, laughter therapy seems to improve endothelial function, immune response, and even energy expenditure, and may have a cardioprotective effect. Thus, it seems appropriate to investigate the effects of this modality in patients with ischemic heart disease, aiming to evaluate its effectiveness for cardiovascular rehabilitation purposes.
Viewing a comedy film sessions (intervention) would provide superior results to viewing documentary sessions (control) on endothelial function and functional capacity in patients with CAD.
To compare the effect of 24 sessions of a comedy film and a neutral documentary on endothelial function and functional capacity in patients with CAD.
To compare the effect of 24 sessions of a comedy film and neutral documentary on inflammatory markers, biochemical parameters, and quality of life.
| Subjects and Methods|| |
This is a randomized, parallel-design, examiner-blinded, controlled clinical trial. Thirty patients will be included (15 in each group). They will be recruited from the outpatient ischemic heart disease clinic of Hospital de Clínicas de Porto Alegre, an 800-bed university hospital in Porto Alegre, Southern Brazil. Endothelial function will be assessed by measurement of brachial-artery FMD at the noninvasive cardiology unit of Hospital de Clínicas de Porto Alegre. The study will be conducted from August 2013 to December 2019. The study protocol was approved by the Institutional Review Board of Hospital de Clínicas de Porto Alegre (protocol No. 13-0124) on July 9, 2013 [Additional file 1]. [Additional file 1] Written informed consent will be obtained from all patients before participation [Additional file 2]. [Additional file 2] The trial protocol was registered in ClinicalTrials.gov (identifier: NCT02824120) and adheres to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidance for protocol reporting [Additional file 3]. [Additional file 3] The current protocol version is 1.0. The schedule of enrollment, interventions, and assessments is presented in [Table 1].
- Age over 18 years
- Diagnosis of CAD established by cardiac catheterization, with a 50% lesion in at least one epicardial vessel (if the patient has a history of acute coronary syndrome or has undergone coronary revascularization, the event should have occurred more than 6 months before enrollment)
- Patients classified as low risk according to the Cardiopulmonary and Metabolic Rehabilitation Guideline (functional capacity ≥ 5 METs, absence of myocardial ischemia at rest or on cardiopulmonary exercise testing, adequate blood pressure response to exertion and ability to self-monitor the intensity of exercise)
- Availability to attend the Hospital de Clínicas de Porto Alegre clinic twice a week
- Fitness to enter an exercise-based cardiac rehabilitation program
- Involvement in another clinical trial
- Presence of autoimmune disease
- Oral anticoagulant therapy
- Mechanical or biological valve replacement for valvular heart disease
- Presence of pacemaker or implantable cardioverter/defibrillator
- Left bundle branch block on 12-lead electrocardiogram
- Severe pulmonary disease
- Major depression or bipolar disorder
- Chronic atrial fibrillation
- Left ventricular dysfunction (left ventricular ejection fraction < 45%)
- Active infection or malignancy (other than basal cell carcinoma)
- Chronic renal failure
- Inability to understand the informed consent form
The project was submitted to the Research Ethics Committee of Hospital de Clínicas de Porto Alegre for consideration. Authorization for subsequent use of obtained data will be requested from all patients involved in the study through the informed consent form. Confidentiality will be ensured according to the applicable legislation. Any questions will be thoroughly answered and discussed. The principal investigator will prospectively monitor any complications arising from the study intervention. The study will be discontinued if any serious side effects resulting from the intervention are identified.
Recruitment and study protocol
First contact with the patients will be established in the outpatient CAD clinic. Eligible patients will be informed of the study and invited to participate; those who accept will be tested by a blinded assessor and randomly allocated to one of the groups. A flow diagram of patient recruitment is shown in [Figure 1].
|Figure 1: Proposed trial design.|
SF-36: 36-Item Short-Form Health Survey; PROMIS: Patient-Reported Outcomes Measurement Information System; HCPA: Hospital de Clínicas de Porto Alegre.
Click here to view
Randomization and blinding
Group allocation will be determined by a random-numbers table generated in IBM SPSS Statistics for Windows, Version 20.0 (IBM Corp., Armonk, NY, USA), and distributed at a 1:1 ratio between the intervention and control groups. The generated codes will be distributed into sequentially numbered, sealed brown envelopes. The investigator in charge of randomization will not participate in the other data collection stages. Outcome assessors will be blinded to group allocation.
Primary and secondary outcomes will be assessed at baseline, after provision of written informed consent but before allocation to one of the study groups. At the end of the 24 sessions, the subject will be evaluated again.
Endothelial function (assessed by brachial artery FMD measurement), functional capacity (assessed by peak oxygen consumption [VO2peak] on cardiopulmonary exercise testing), a broad panel of inflammatory markers in blood (high-sensitivity C-reactive protein, tumor necrosis factor-alpha, vascular cell adhesion molecule 1, intercellular adhesion molecule 1, interleukin-6, interleukin-10), biochemical parameters (total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, cortisol, glucose, complete blood count, potassium, renin, thyroid-stimulating hormone, and troponin T), and quality of life will be measured.
Patients will perform two 30-minute weekly stretching sessions for 2 months (two sessions per week, for a total 24 sessions). The exercises will be of mild to moderate intensity (modified Borg scale 3–6). After each stretching class, participants will watch a 30-minute film, selected according to group allocation.
Briefly, after randomization, patients who are allocated to the comedy film group will receive a list of several comedy television series, and are asked to choose those they find most amusing. Episodes of these series will then be shown as the intervention after each stretching session. Conversely, individuals allocated to the control group will watch a 30-minute neutral documentary (defined as one that does not cause exacerbated emotions of sadness or joy), selected by the investigators, after each stretching session.
Before and after each session, appropriate scales will be used to evaluate the participants’ mood.
The intervention will take place at the Department of Physical Medicine and Rehabilitation of Hospital de Clínicas de Porto Alegre. Staff physical educators will serve as instructors for the stretching sessions, according to the protocol described in [Table 2].
At the start of each exercise session, blood pressure and resting heart rate will be measured. Blood pressure will also be measured immediately after training and at 3 minutes of recovery. Participants will be allowed to relax in the seated position for at least 3 to 5 minutes before blood pressure measurements. The arm will be stretched, aligned with the mid-sternum, and supported. A properly sized cuff will be wrapped around the arm and attached to an aneroid sphygmomanometer, and blood pressure measured by the auscultation method as described elsewhere. At least two blood pressure measurements will be obtained in the sitting position, 1 to 2 minutes apart; additional measurements will be obtained if the first two are markedly discrepant.
Heart rate will be monitored before, during, and up to 3 minutes after exertion with a Polar Fitness FS1 heart rate monitor (Polar, Finland). The physical educators who will guide the exercise sessions are trained in basic life support. All sessions will be supervised by a multidisciplinary team consisting of an attending physician, an assistant physician, a physical educator, and a psychologist.
All patients will be advised to seek immediate care at the Emergency Department of Hospital de Clínicas de Porto Alegre if any untoward event occurs during the study period. They will also carry identification cards bearing their name, medical record number, and guidance for immediate transfer to the Emergency Department of Hospital de Clínicas de Porto Alegre if they are taken to any other medical facility in the city of Porto Alegre or neighboring municipalities.
The primary outcome measures are endothelial function and functional capacity; the secondary outcomes include a complete lipid profile, a wide-ranging panel of markers on inflammation, routine blood tests, and quality of life assessment. A detailed description is provided in the “Baseline measures” section above.
Measurement of main variables
Noninvasive measurements of endothelial function will be obtained by FMD of the brachial artery using two-dimensional ultrasound equipment. FMD measurement will be performed in accordance with published guidelines. Briefly, the examination will start after 15 minutes of rest in a temperature-controlled room, with the patient supine and arms in a comfortable position. Any vasodilation medication will be discontinued at least 4 hours before the examination, if possible. Individuals will also be advised to refrain from exercising, drinking caffeine, and smoking for at least 4 hours before the examination.
Cardiopulmonary exercise testing with expired gas analysis will be performed on a treadmill (Inbramed KT 10200, Inbramed, Porto Alegre, Brazil, speed 0–16 km/h [0–10 mph], grade 0–26%). A ramp protocol will be used, with a starting speed of 2.4 km/h and a starting grade of 2%; speed will be increased every 20 seconds in 0.1- or 0.2-km/h increments, and grade, every 60 seconds in 0.1–0.2% increments. The objective is to achieve fatigue within 8 to 12 minutes (mean, 10 minutes). During the pretest phase, participants will walk for 1 to 3 minutes at a gentle pace to adapt to the treadmill. Heart rate will be monitored with a 12-lead electrocardiograph (Nihon Kohden Corporation, Tokyo, Japan), with electrode placement as described by Mason and Lika.
Blood chemistry and biomarkers of inflammation
Total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, cortisol, glucose, complete blood count, potassium, high-sensitivity C-reactive protein, renin, thyroid-stimulating hormone, triglycerides, troponin T, tumor necrosis factor-alpha, vascular cell adhesion molecule 1, intercellular adhesion molecule 1, interleukin-6, and interleukin-10 will be measured in blood samples.
Part of each blood sample will be taken immediately to the Hospital de Clínicas de Porto Alegre laboratory for analysis of lipid profile and blood sugar. The other part will be centrifuged at 4°C and 2879 × g for 10 minutes in an ALC PK 120 R centrifuge (ALC International, Milan, Italy) and the serum will be frozen at –80°C in labeled Eppendorf tubes for quantization of inflammatory biomarkers.
Quality of life
The 36-Item Short-Form Health Survey generic questionnaire will be used to assess quality of life on eight domains: vitality, physical functional capacity, pain, general health perception, physical role functioning, social role functioning, emotional role functioning, and mental health. The 36-Item Short-Form Health Survey scores range from 0 to 100 for each parameter.
Sample size calculation
As there are no previous studies in this specific area of knowledge, our calculation was based on an experiment by Miller et al., who enrolled healthy subjects and compared the effect of mental stress versus laughter therapy on endothelial function. For a statistical power of 95%, an alpha error rate of 5%, and an absolute difference of 2.6 (1.9%) in FMD between groups, we calculated a total sample of 24 patients. Considering 20% attrition in the overall sample, 30 subjects (n = 15/group) will need to be enrolled.
Data management and monitoring
Due to minimal risks associated with the interventions and short duration of the trial, no Data Monitoring Committee will be established, nor will interim analyses be performed.
Data will be entered and coded into a Microsoft Excel 14.7.7 spreadsheet (Microsoft Corporation, Redmond, WA, USA). Categorical variables will be presented as absolute frequencies and percentages. Continuous variables with normal distribution will be expressed as mean and standard deviation, and those without normal distribution, as median and interquartile range. The chi-square test will be used to analyze categorical variables. For within-group comparison of quantitative variables before and after the intervention, Student’s t-test for paired samples (for normally distributed variables) and the Wilcoxon test (for non-normally distributed variables) will be used. Between-group comparisons of changes in outcome variables will be done by analysis of covariance, using baseline values to adjust for later results. The Kruskal-Wallis test will be used to verify the assumption of normality.
The level of significance will be set at 5% (two-tailed) for all tests. All data will be analyzed in IBM SPSS Statistics for Windows, Version 20.0 (IBM Corp., Armonk, NY, USA), by the intention-to-treat method.
| Discussion|| |
To the best of our knowledge, this will be the first study to evaluate the effect of laughter therapy in adults with CAD. This experiment will provide an opportunity to evaluate the effect of this type of therapy in these patients in a routine clinical practice setting.
Laughter is a unique human response to humorous stimuli. It is also believed to act as a coping mechanism to reduce stress; it improves self-esteem and reduces psychological symptoms related to negative events., In addition to these notable psychological benefits, laughter has physical repercussions, with possible gains attributed to reduction of muscle tension, enhanced oxygenation, and increased cardiac work. Growing research in the field of laughter therapy is based on the assumption that these physiological changes can be beneficial to the cardiovascular system.
Many advances have been made in determining the impact of endothelial function on the prognosis and rehabilitation of individuals with CAD. Despite the relevant finding that FMD of the brachial artery is an important marker in atherosclerosis; studies on its prognostic value are quite recent. Endothelial response is emerging as a prospective addition to the armamentarium for individual risk assessment and, perhaps, even as a potential therapeutic target.
Within this context, laughter has been shown to influence endothelial function. Sugawara et al. determined the effects of mirthful laughter (i.e., that elicited as a genuine response to a humorous stimulus) on endothelial function and central artery compliance. In a crossover trial design, apparently healthy adults (age 23 to 42 years) watched 30 minutes of a comedy film (intervention) or a documentary (control) on separate days. Ischemia-induced FMD of the brachial artery (measured by mode B ultrasonography) increased significantly after watching the comedy (17%) and decreased after watching the documentary (–15%). Carotid artery compliance (measured by simultaneous carotid ultrasound and applanation tonometry) increased 10% immediately after watching the comedy, returning to baseline within 24 hours. These changes were significantly associated with baseline FMD (r = 0.63). Conversely, exposure to the documentary did not affect carotid compliance. The authors concluded that mirthful laughter elicited by comic films has a beneficial impact on vascular function.
Similar findings were reported by Vlachopoulus et al., who investigated the effects of film-elicited laughter on arterial stiffness. In their study, healthy subjects watched three different films at random: a stressful film, a comedy, and a placebo in which nothing was projected. Comedy reduced pulse-wave velocity and arterial stiffness. Miller et al. compared FMD in 20 healthy subjects during 15 to 30 minutes of laughter-inducing films and stress-inducing films. FMD was found to increase 22% after watching a comedy and reduce 47% after watching a stressful film.
Given the high prevalence and ominous mortality of cardiovascular diseases, we believe there is an important need to investigate the benefits of laughter therapy; a simple, safe, and inexpensive therapeutic alternative that, in addition to improving quality of life, may exert a positive influence on physiological and biochemical parameters in patients with stable CAD.
| Trial Status|| |
The current protocol version is 1.0. Patient recruitment will end in December 2019. Analysis of the primary outcome measure will be completed in December 2019.
Additional file 1: Ethical approval documentation.
Additional file 2: Model consent form.
Additional file 3: SPIRIT checklist.
All authors contributed to the conception, design, literature search, and critical review of the manuscript for important intellectual content. All authors gave final approval for publication.
Conflicts of interest
This study was supported by Funding for Research and Events from the Hospital de Clínicas de Porto Alegre (FIPE-HCPA).
Institutional review board statement
The study protocol was approved by the Institutional Review Board of Hospital de Clínicas de Porto Alegre (protocol No. 13-0124) on July 9, 2013.
Declaration of patient consent
The authors certify that they will obtain all appropriate consent from participant. In the forms the patients will give their consent for their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity forms.
This study followed the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidance for protocol reporting.
A staff statistician at Hospital de Clínicas de Porto Alegre reviewed the statistical methods of this study.
Copyright license agreement
The Copyright License Agreement has been signed by the first author before publication.
Data sharing statement
Anonymized individual data will be available immediately after study publication upon request from those who wish to access the data for 5 years. If anonymized data is provided, it should be done so after proposals to [email protected] Raw data will be stored in a locked cabinet at the Hospital de Clínicas de Porto Alegre for this time period before being destroyed. Personal results will also be available to participants upon request. If requested, study protocols and outputs of statistical analysis will be available.
Checked twice by iThenticate.
Externally peer reviewed.
Open access statement
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
C-Editor: Zhao M; S-Editors: Li CH, Li JY; L-Editors: Qiu Y, Wang L; T-Editor: Jia Y
| References|| |
Diederichs C, Neuhauser H, Rücker V, et al. Predicted 10-year risk of cardiovascular mortality in the 40 to 69 year old general population without cardiovascular diseases in Germany. PLoS One
Mampuya WM. Cardiac rehabilitation past, present and future: an overview. Cardiovasc Diagn Ther
Cortés O, Arthur HM. Determinants of referral to cardiac rehabilitation programs in patients with coronary artery disease: a systematic review. Am Heart J
O’Connor GT, Buring JE, Yusuf S, et al. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation
Lu WA, Kuo CD. The effect of Tai Chi Chuan on the autonomic nervous modulation in older persons. Med Sci Sports Exerc
Martin RA. Humor, laughter, and physical health: methodological issues and research findings. Psychol Bull
Azambuja MI, Foppa M, Maranhão MF, Achutti AC. Economic burden of severe cardiovascular diseases in Brazil: an estimate based on secondary data. Arq Bras Cardiol
Ribeiro RA, Mello RG, Melchior R, et al. Annual cost of ischemic heart disease in Brazil. Public and private perspective. Arq Bras Cardiol
9. Fry WF. The physiological effects of humor, mirth and laughter. JAMA
Lebowitz K R, Suh S, Diaz PT, Emery CF. Effects of humor and laughter on psychological functioning, quality of life, health status, and pulmonary functioning among patients with chronic obstructive pulmonary disease: A preliminary investigation. Heart Lung
Brutsche MH, Grossman P, Müller RE, et al. Impact of laughter on air trapping in severe chronic obstructive lung disease. Int J Chron Obstruct Pulmon Dis
Sugawara J, Tarumi T, Tanaka H. Effect of mirthful laughter on vascular function. Am J Cardiol
Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med
Sociedade Brasileira de C. Guideline for cardiopulmonary and metabolic rehabilitation: practical aspects. Arq Bras Cardiol
Mancia G, Fagard R, Narkiewicz K, et al. ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens
Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol
Mason RE, Likar I. A new system of multiple-lead exercise electrocardiography. Am Heart J
Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care
Miller M, Mangano C, Park Y, Goel R, Plotnick GD, Vogel RA. Impact of cinematic viewing on endothelial function. Heart
Lebowitz KR, Suh S, Diaz PT, Emery CF. Effects of humor and laughter on psychological functioning, quality of life, health status, and pulmonary functioning among patients with chronic obstructive pulmonary disease: a preliminary investigation. Heart Lung
Bennett MP, Lengacher CA. Humor and Laughter May Influence Health. II. Complementary therapies and humor in a clinical population. Evid Based Complement Alternat Med
Buchowski MS, Majchrzak KM, Blomquist K, Chen KY, Byrne DW, Bachorowski JA. Energy expenditure of genuine laughter. Int J Obes
Vlachopoulos C, Xaplanteris P, Alexopoulos N, et al. Divergent effects of laughter and mental stress on arterial stiffness and central hemodynamics. Psychosom Med
Garcia MMO, Lima PRP, Correia LCL. Valor Prognóstico da Função Endotelial em Portadores de Aterosclerose: Revisão Sistemática. Arq Bras Cardiol
[Table 1], [Table 2]